GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial

What Was Tested

This randomized controlled trial looks at hCG (human chorionic gonadotropin).

Who Took Part

According to the abstract, 194 patients were involved.

PubMed indexes the participants as adults, women only.

A total of 194 patients undergoing a IVF/ICSI GnRH antagonist cycle that were at risk of OHSS and chose to proceed with embryo transfer and avoid cycle cancellation or embryo cryopreservation were allocated into two groups.

The inclusion criteria consisted of a rapid rise of oestradiol ≥ 3500 pg/ml combined with ≥ 18 follicles > 11 mm in diameter without any mature follicle > 16 mm, in any day of stimulation.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

This is a prospective randomized control study, conducted from November 2012 to January 2016.

What Was Measured

PubMed files the paper under topics including Chorionic Gonadotropin, Embryo Implantation, Embryo Transfer, Estradiol, Fertilization in Vitro, Gonadotropin-Releasing Hormone and Hormone Antagonists.

Author keywords: GnRH antagonists, IVF-ICSI, OHSS and Ovarian stimulation.

What This Means in Plain Language

The paper is a randomized study of hCG (human chorionic gonadotropin) in 194 patients.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Journal of assisted reproduction and genetics), a journal based in Netherlands.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.